Počet záznamů: 1
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
- 1.0521329 - BTÚ 2020 RIV US eng J - Článek v odborném periodiku
Průková, D. - Anděra, Ladislav - Nahácka, Zuzana - Karolová, J. - Svaton, M. - Klanova, M. - Havranek, O. - Soukup, J. - Svobodová, K. - Zemanová, Z. - Tušková, D. - Pokorná, E. - Helman, K. - Forsterova, K. - Pacheco-Blanco, M. - Vockova, P. - Berková, A. - Froňková, E. - Trněný, M. - Klener, P.
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.
Clinical Cancer Research. Roč. 25, č. 14 (2019), s. 4455-4465. ISSN 1078-0432. E-ISSN 1557-3265
Institucionální podpora: RVO:86652036
Klíčová slova: acute myeloid-leukemia * open-label * cancer * landscape
Obor OECD: Oncology
Impakt faktor: 10.107, rok: 2019
Způsob publikování: Open access
https://clincancerres.aacrjournals.org/content/25/14/4455
Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over) expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of venetoclax resistance in MCL cells and tested strategies to overcome it.
Trvalý link: http://hdl.handle.net/11104/0305960
Počet záznamů: 1